Write in a clean editor, then format for Therapeutic Advances in Hematology in one click — DocuGuru applies the official SAGE template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Therapeutic Advances in Hematology is a peer-reviewed journal published by SAGE, covering Lymphoma Diagnosis and Treatment, Acute Myeloid Leukemia Research, Chronic Lymphocytic Leukemia Research.
| Publisher | SAGE |
|---|---|
| Reference style | Author–year (Harvard) Author–year — (Smith, 2023) in the text Smith, A., Jones, B. and Lee, C. (2023) 'A representative article title', Therapeutic Advances in Hematology, 12(3), pp. 45–58.
Formats any DOI in Therapeutic Advances in Hematology style. No sign-up. |
| Publishes research in | Lymphoma Diagnosis and Treatment Acute Myeloid Leukemia Research Chronic Lymphocytic Leukemia Research Multiple Myeloma Research and Treatments Hematopoietic Stem Cell Transplantation |
| ISSN | 2040-6207 |
| Citation impact (2-yr) | 2.22 |
| h-index | 55 |
| i10-index | 347 |
| Total citations | 13,471 |
| Article processing charge | $2,300 |
| Open access | Yes |
| Top institutions publishing here | The University of Texas MD Anderson Cancer Center |
| Journal website | us.sagepub.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Myeloid sarcoma is a rare disease that can present as an isolated extramedullary leukemic tumor, concurrently with or at relapse of acute myeloid leukemia. Owing to the rarity of this disorder, most of the literature comprises small retrospective studies and case reports. The aim of this review is to summarize the current published data regarding…
Factor VIII (FVIII) replacement therapy is the foundation of treatment in hemophilia A and is effective unless a patient develops an alloantibody (inhibitor) against exogenous FVIII. Inhibitor development is currently the most significant treatment complication seen in patients with hemophilia and is associated with considerable morbidity and a decreased quality of life. The development of…
Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cell has changed the treatment landscape of B-cell non-Hodgkin's lymphoma (NHL), especially for aggressive B-cell lymphomas. Single-center and multicenter clinical trials with anti-CD19 CAR T-cell therapy have shown great activity and long-term remissions in poor-risk diffuse large B-cell lymphoma (DLBCL) when no other effective treatment options…
Graft-versus-host disease (GVHD) is a significant cause of morbidity and mortality following allogenic haematopoietic stem-cell transplantation and thus the focus of much ongoing research. Despite considerable advances in our understanding of the pathophysiology, diagnosis and predisposing factors for both acute and chronic forms of the disease, a standardised therapeutic strategy is still lacking. There is…
Perhaps no other drug in modern medicine rivals the dramatic revitalization of thalidomide. Originally marketed as a sedative, thalidomide gained immense popularity worldwide among pregnant women because of its effective anti-emetic properties in morning sickness. Mounting evidence of human teratogenicity marked a dramatic fall from grace and led to widespread social, legal and economic ramifications.…
